Interestingly the only patient in whom treatment with Omalizumab had to be resumed nine months after discontinuation due to inadequate asthma control showed at T1 elevated FeNO levels (105 ppb), increased total serum IgE (812 KU/L) and blood eosinophil counts (220 cells/μl). The gene discussed is IGHE; the disease is asthma.